Adding Ketamine to Levobupivacaine in Paravertebral Block in Thoracotomy
CompletedPhase 4NCT06011746
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To evaluate the role of adding ketamine to levobupivacaine in PVB on acute and chronic pain in thoracotomy
Study details
- Official title
- Efficacy of Adding Ketamine to Levobupivacaine in Paravertebral Block on Acute and Chronic Pain in Thoracotomy: a Randomized Controlled Double-blinded Trial
- Conditions
- Ketamine
- Levobupivacaine
- Paravertebral Block
- Acute Pain
- Chronic Pain
- Interventions
- Drug: Ketamine + Levobupivacaine
- Drug: Levobupivacaine
- Sponsor
- Tanta University
- Start date
- 2023-08-30
- Primary completion
- 2024-01-26
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18-75 years. * Both sexes. * ASA (American Society of Anesthesiology) physical status II-III. * Scheduled for open thoracotomy. Exclusion Criteria: * Contraindications to or failed paravertebral block . * Body mass index (BMI) \>35 kg/m2. * The likelihood of postoperative mechanical ventilation. * Patients with coagulopathy, poorly controlled diabetes mellitus, depression or other psychiatric disorders that required antidepressant drugs, alcohol, or recreational drug addiction. * Hypersensitivity to ketamine or levobupivacaine.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06011746